Molecular imaging firm Blue Earth Diagnostics is touting 16 presentations involving its Axumin (fluciclovine F-18) PET radiopharmaceutical and "radiohybrid" prostate-specific membrane antigen (F-18 rhPSMA-7) imaging agent at next week's Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
The studies include clinical use of Axumin, investigational use of fluciclovine F-18, and initial clinical experience with F-18 rhPSMA-7. The scientific presentations will cover advances in imaging for prostate cancer, glioma, breast cancer, and various gynecological cancers, according to the firm.
